CollPlant Biotechnologies (CLGN) vs Longeveron (LGVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Longeveron is the larger company by market cap ($7.9 million vs $6.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLGN | LGVN |
|---|---|---|
| Share price | $3.51 | $2.48 |
| Market cap | $6.64M | $7.91M |
| 1-day change | -11.59% | +4.64% |
| EPS (TTM) | $-9.33 | $-9.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.80 | $12.30 |
| 52-week low | $2.64 | $2.30 |
| Distance from 52-week high | -86.90% | -79.84% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +2369.76% |
| Average volume | 352.86K | 92.38K |
| Shares outstanding | 1.89M | 3.04M |
| Employees | 39 | 38 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CollPlant Biotechnologies
CLGN stock →CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology.
Health Care · Industrial Specialties · 39 employees
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
CLGN vs LGVN FAQ
Which is bigger, CollPlant Biotechnologies or Longeveron?
Longeveron (LGVN) is larger, with a market capitalization of $7.91M compared with $6.64M for CollPlant Biotechnologies (CLGN).
Are CollPlant Biotechnologies and Longeveron in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for CollPlant Biotechnologies and Biotechnology: Pharmaceutical Preparations for Longeveron.